Feasibility and acceptability of patient- and clinician-level antithrombotic stewardship interventions to reduce gastrointestinal bleeding risk in patients using warfarin (Anticoagulation with Enhanced Gastrointestinal Safety): a factorial randomized controlled pilot trial

IF 3.4 3区 医学 Q2 HEMATOLOGY
Jacob E. Kurlander , Danielle Helminski , Liyang Yuan , Sarah L. Krein , Michael S.M. Lanham , Jennifer L. Henstock , Kelley M. Kidwell , Raymond De Vries , Kenneth Resnicow , Haden Sholl , Joyce J. Kim , Linda K. Perry , Jacqueline Parsons , Nghi Ha , James B. Froehlich , James E. Aikens , Caroline R. Richardson , Sameer D. Saini , Geoffrey D. Barnes
{"title":"Feasibility and acceptability of patient- and clinician-level antithrombotic stewardship interventions to reduce gastrointestinal bleeding risk in patients using warfarin (Anticoagulation with Enhanced Gastrointestinal Safety): a factorial randomized controlled pilot trial","authors":"Jacob E. Kurlander ,&nbsp;Danielle Helminski ,&nbsp;Liyang Yuan ,&nbsp;Sarah L. Krein ,&nbsp;Michael S.M. Lanham ,&nbsp;Jennifer L. Henstock ,&nbsp;Kelley M. Kidwell ,&nbsp;Raymond De Vries ,&nbsp;Kenneth Resnicow ,&nbsp;Haden Sholl ,&nbsp;Joyce J. Kim ,&nbsp;Linda K. Perry ,&nbsp;Jacqueline Parsons ,&nbsp;Nghi Ha ,&nbsp;James B. Froehlich ,&nbsp;James E. Aikens ,&nbsp;Caroline R. Richardson ,&nbsp;Sameer D. Saini ,&nbsp;Geoffrey D. Barnes","doi":"10.1016/j.rpth.2024.102421","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Overuse of antiplatelet therapy and underuse of gastroprotection contribute to preventable bleeding in patients taking anticoagulants.</p></div><div><h3>Objectives</h3><p>(1) Determine the feasibility of a factorial trial testing patient activation and clinician outreach to reduce gastrointestinal (GI) bleeding risk in patients prescribed warfarin–antiplatelet therapy without proton pump inhibitor gastroprotection and (2) assess intervention acceptability.</p></div><div><h3>Methods</h3><p>Pragmatic 2 × 2 factorial cluster-randomized controlled pilot comparing (1) a patient activation booklet vs usual care and (2) clinician notification vs clinician notification plus nurse facilitation was performed. The primary feasibility outcome was percentage of patients completing a structured telephone assessment after 5 weeks. Exploratory outcomes, including effectiveness, were evaluated using chart review, surveys, and semistructured interviews.</p></div><div><h3>Results</h3><p>Among 47 eligible patients, 35/47 (74.5%; 95% CI, 58.6%-85.7%) met the feasibility outcome. In the subset confirmed to be high risk for upper GI bleeding, 11/29 (37.9%; 95% CI, 16.9%-64.7%) made a medication change, without differences between intervention arms. In interviews, few patients reported reviewing the activation booklet; barriers included underestimating GI bleeding risk, misunderstanding the booklet’s purpose, and receiving excessive health communication materials. Clinicians responded to notification messages for 24/47 patients (51.1%; 95% CI, 26.4%-75.4%), which was lower for surgeons than nonsurgeons (22.7% vs 76.0%). Medical specialists but not surgeons viewed clinician notification as acceptable.</p></div><div><h3>Conclusion</h3><p>The proposed trial design and outcome ascertainment strategy were feasible, but the patient activation intervention is unlikely to be effective as designed. While clinician notification appears promising, it may not be acceptable to surgeons, findings which support further refinement and testing of a clinician notification intervention.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924001109/pdfft?md5=d5f3134d095a4651733a2ff311199f53&pid=1-s2.0-S2475037924001109-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practice in Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2475037924001109","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Overuse of antiplatelet therapy and underuse of gastroprotection contribute to preventable bleeding in patients taking anticoagulants.

Objectives

(1) Determine the feasibility of a factorial trial testing patient activation and clinician outreach to reduce gastrointestinal (GI) bleeding risk in patients prescribed warfarin–antiplatelet therapy without proton pump inhibitor gastroprotection and (2) assess intervention acceptability.

Methods

Pragmatic 2 × 2 factorial cluster-randomized controlled pilot comparing (1) a patient activation booklet vs usual care and (2) clinician notification vs clinician notification plus nurse facilitation was performed. The primary feasibility outcome was percentage of patients completing a structured telephone assessment after 5 weeks. Exploratory outcomes, including effectiveness, were evaluated using chart review, surveys, and semistructured interviews.

Results

Among 47 eligible patients, 35/47 (74.5%; 95% CI, 58.6%-85.7%) met the feasibility outcome. In the subset confirmed to be high risk for upper GI bleeding, 11/29 (37.9%; 95% CI, 16.9%-64.7%) made a medication change, without differences between intervention arms. In interviews, few patients reported reviewing the activation booklet; barriers included underestimating GI bleeding risk, misunderstanding the booklet’s purpose, and receiving excessive health communication materials. Clinicians responded to notification messages for 24/47 patients (51.1%; 95% CI, 26.4%-75.4%), which was lower for surgeons than nonsurgeons (22.7% vs 76.0%). Medical specialists but not surgeons viewed clinician notification as acceptable.

Conclusion

The proposed trial design and outcome ascertainment strategy were feasible, but the patient activation intervention is unlikely to be effective as designed. While clinician notification appears promising, it may not be acceptable to surgeons, findings which support further refinement and testing of a clinician notification intervention.

患者和临床医生层面的抗血栓管理干预措施对降低华法林患者胃肠道出血风险的可行性和可接受性(加强胃肠道安全的抗凝治疗):因子随机对照试验
背景抗血小板疗法的过度使用和胃保护剂的使用不足导致了服用抗凝剂的患者发生可预防的出血。目的(1)确定一项因子试验的可行性,该试验测试了患者激活和临床医生宣传以降低处方华法林-抗血小板疗法但未使用质子泵抑制剂胃保护剂的患者的胃肠道(GI)出血风险;(2)评估干预措施的可接受性。方法进行了务实的 2 × 2 因式分组随机对照试验,比较了(1)患者激活手册与常规护理;(2)临床医生通知与临床医生通知加护士协助。主要可行性结果是 5 周后完成结构化电话评估的患者百分比。结果在 47 名符合条件的患者中,35/47(74.5%;95% CI,58.6%-85.7%)人达到了可行性结果。在被确认为上消化道出血高危人群中,11/29(37.9%;95% CI,16.9%-64.7%)名患者更换了药物,干预组之间没有差异。在访谈中,很少有患者表示查看了激活手册;障碍包括低估了消化道出血风险、误解了手册的目的以及收到了过多的健康宣传材料。临床医生回复了 24/47 例患者的通知信息(51.1%;95% CI,26.4%-75.4%),外科医生的回复率低于非外科医生(22.7% vs 76.0%)。结论 拟议的试验设计和结果确定策略是可行的,但患者激活干预措施不太可能像设计的那样有效。虽然临床医生通知似乎很有前景,但外科医生可能无法接受,这些结果支持进一步完善和测试临床医生通知干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
13.00%
发文量
212
审稿时长
7 weeks
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信